Antibody-Drug Conjugates-Evolution and Perspectives

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Antineoplastic therapy aims to improve cancer treatment efficacy and reduce side effects.
• Antibody-drug conjugates (ADCs) are an advanced strategy for targeted drug delivery in cancer therapy.

Purpose of the Study:

• To review various aspects of antibody-drug conjugates (ADCs).
• To discuss the chemical and pharmacological perspectives of ADCs, including their structure, conjugation, development, effects, clinical trials, safety, and future challenges.

Main Methods:

• Review of existing literature on antibody-drug conjugates.
• Analysis of ADC components: monoclonal antibodies, linkers, and payloads.
• Discussion of clinical trial data, safety profiles, and future development strategies.

Main Results:

• ADCs offer a targeted approach to cancer treatment, enhancing drug efficacy and minimizing systemic toxicity.
• Key structural components include monoclonal antibodies (e.g., trastuzumab), various linkers, and potent cytotoxic payloads (e.g., doxorubicin, emtansine).
• Numerous ongoing clinical trials support the high expectations for ADC therapeutic success.

Conclusions:

• ADCs represent a significant advancement in antineoplastic therapy.
• Addressing challenges in development, safety, and efficacy is crucial for maximizing the potential of ADCs.
• Future research will focus on overcoming current limitations and expanding ADC applications in cancer treatment.